Markets entry

High development costs and extensive product application work are required for market entry. 

We now conclude this work by showing how differences in regulation can account for such substantial differences in competition between one country and the other. We focus our attention on three aspects first, we discuss the differences in market entry regulations, then we go on to describe the differences in price regulations, and finally, we show the differences that exist in demand-side pohdes within the respective public health systems. 

In conclusion, we could say that entry requirements are justified inasmuch as they are necessary to guarantee the effectiveness or efficiency of pharmaceuticals. However, establishing or maintaining unnecessary requirements to this end is tantamount to establishing costs that constitute barriers to market entry which some companies, especially smaller ones, will be unable to clear. Ultimately, these barriers also weaken competition and the consequent possibility of prices being forced down. 

In order to analyse the balance in view of the threat of exclusion from public financing, the author devises a demand equation with a two-stage budget allocation. The first step is to choose a therapeutic group, and the second is to choose the differentiated products. The co-payment acts as the price. The main conclusion is that when the product is included in public financing the health service can receive a discount if the political decisions are price-sensitive and the fixed cost of market entry in the event of inclusion is lower than the fixed cost of exclusion. In his study of price-cap regulation, the author insists that the mechanism should be continued in the long term, and that therefore it is necessary to account for the entire lifetime of the product and consider a discount factor. All this takes as its point of departure Abbott s 1995 model. 

The challenges facing the pharmaceutical industry in 2012 are significant. There is a perceived decline in the productivity of R and D, significantly higher regulatory hurdles to market entry (particularly in the key US market),... 

Eventual market entry and forecasted revenue generation impacts a firm s financial outlook. 

Market entry cost high N cost goals not demonstrated. 

Fuel Cell Energy expects to have its initial market entry MCFC power systems available in the year 2001, with mature megawatt class units projected to be available in 2004. These units will be produced in various sizes. Preliminary cycle information was received from FCE for a nominal 3 MW power plant. This cycle is presented in Figure 9-9 and is described below. 

The study focuses solely on the procedures used to facilitate generic drug market entry prior to expiration of the patent(s) that protect the brand-name drug product. The study does not address other procedures for generic entry, and it does not address the patent restoration features of Hatch-Waxman. 

The almost immediate commercial success of the gonane-based oral contraceptives spurred an impressive amount of work in this series aimed at developing new market entries. Describing each of those in detail is beyond the scope of this volume instead, we present below some examples chosen almost arbitrarily because their synthesis involves some interesting chemistry. 

The measures for actively raising awareness at the market entry stage include, among others, advertisements in special-interest magazines, presentations at trade fairs, training programmes, and the participation in information events. The BMLFUW s subsidy schemes also add to the incentives for potential customers to adopt the business model. 

---